Clinical trials: Multiple Sclerosis Relapsing Remitting
Relapsing Remitting Multiple Sclerosis
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
- Trial name
- NCT05181215
- Testing
- Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Progressive Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs and the…
- Trial name
- VASOSEP (NCT02580669)
- Testing
- Neuropsychological assessment, Neurologic consultation, MRIs (with vasoreactivity testing)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cortical Lesions in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease, leading to inflammation and degeneration of neurons in the entire central nervous system (CNS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- CLiMS (NCT03653585)
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Multiple Sclerosis, Relapsing-Remitting
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)
The study is a two-year prospective observational study of patients treated with teriflunomide. The investigators will recruit up to 75 patients at baseline, based on the estimate that approximately 20% of these patients (~ 15…
- Trial name
- NCT03561402
- Testing
- Teriflunomide
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McGill University
Multiple Sclerosis (MS), Multiple Sclerosis (MS) Relapsing Remitting
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
This study aims to: analyze prospectively the prevalence of subclinical oculomotor disorders (OMDs) in different phenotypes of Multiple Sclerosis (MS) and to study correlations with brain MRI T2 data.
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis (MS) Relapsing Remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- EYE-SEP (NCT04705610)
- Testing
- Video-oculography / Social cognition tasks / Neuropsychological evaluations
- Where
- Monaco
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences
Multiple Sclerosis, Relapsing-Remitting
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic immune central nervous system (CNS) disease of unknown cause. Recent studies suggest that gut microbiota could be a trigger for the neuro-inflammation in MS and abnormal gut microbiota…
- Trial name
- NCT03975413
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Relapsing Remitting Multiple Sclerosis
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
- Trial name
- NCT02258217
- Testing
- Acthar
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- OhioHealth
Multiple Sclerosis
Gene Expression Profiles in Multiple Sclerosis (MS)
The purpose of this study is to test differences in RNA levels between Multiple Sclerosis (MS) patients and normal subjects. RNA provides a "message" from genes altered in diseases.
- Trial name
- NCT00704834
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Relapsing Remitting Multiple Sclerosis, Fatigue
Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients
The main purpose of the study is to assess the fatigue, cognition, quality of life and disability correlation to MS-patients daily physical activity.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Fatigue, Quality of Life, Physical Activity
- Trial name
- PAMS (NCT04115930)
- Testing
- Physical Activity measurement:
- Where
- 4 sites in Finland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Multiple Sclerosis, Relapsing-remitting
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels.
- Trial name
- NCT01667796
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis
The aim of the study is to investigate reliability, validity, and responsiveness of the timed 360° turn test in patients with Multiple Sclerosis.
- Trial name
- NCT03718026
- Testing
- The timed 360° turn test
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Gazi University
Pediatric Multiple Sclerosis
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
The purpose of this study is to better understand multiple sclerosis (MS) in children and adolescents, to learn if it differs from adult MS and to investigate if genes or environmental exposures or a combination of both put…
- Trial name
- NCT01396343
- Where
- 17 sites in United States
- Volunteers
- 1,276 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis, Relapsing-Remitting
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
This is an exploratory study, which allows analysis of multiple immune parameters derived from peripheral blood mononuclear cells (PBMCs) from patients with relapsing remitting multiple sclerosis before and during…
- Trial name
- DIMAT-MS (NCT02461069)
- Testing
- Dimethyl fumarate
- Where
- 6 sites in Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
RELAPSING REMITTING MULTIPLE SCLEROSIS
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion.
- Trial name
- NCT02833714
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Study Using 3 Different Formulations of Firategrast
This study will investigate how 3 types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01416363
- Testing
- Firategrast immediate release tablet, Firategrast modified release tablet, Firategrast gastro-retentive solution
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
- Trial name
- P1A114347 (NCT01431937)
- Testing
- GSK2018682
- Where
- 3 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
This study will investigate how 3 new types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01424462
- Testing
- A, B, C
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a 3-part study where Parts A, B (single-blind - investigator and subject blind) will enrol healthy volunteers and Part C (open-label) will enrol RRMS patients.
- Trial name
- NCT01808482
- Testing
- Part A: 100 mg/mL GSK2618960, Part B: Dose of GSK2618960 decided from Part A, Part C: Dose of GSK2618960 decided from Part A and B
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline